Mexico - Delayed Quote MXN

AstraZeneca PLC (AZNN.MX)

1,345.00

0.00

(0.00%)

At close: May 21 at 12:12:08 PM CST

AstraZeneca (LSE:AZN) Gains EU Recommendation For Imfinzi in Bladder Cancer Treatment

AstraZeneca (LSE:AZN) received a positive recommendation from the European Medicines Agency for its cancer therapy Imfinzi, marking a significant advancement in its oncology portfolio. Despite this favorable development, the company's stock movement was flat last week. This aligns with broad market trends, where major indexes experienced fluctuations driven by global trade policy changes, yet also registered flat movement due to the tech sector's strong performance. AstraZeneca's active role...

Simply Wall St. 3 hours ago

AZN

AZNCF
AZN Gets CHMP Nod for Imfinzi in Muscle-Invasive Bladder Cancer

AstraZeneca wins CHMP nod for Imfinzi combo in muscle-invasive bladder cancer, based on data from the phase III NIAGARA study.

Zacks 6 hours ago

AZN
Roche Gets CHMP Nod for Itovebi Combo in the EU for Breast Cancer

RHHBY's Itovebi combo wins CHMP backing for PIK3CA-mutated breast cancer, showing strong survival benefits in phase III INAVO120 study.

Zacks yesterday

ROG.SW

PFE

AZN
European Equities Close Sharply Lower in Friday Trading; German Q1 GDP Expands 0.4% Sequentially

The European stock markets fell sharply in Friday trading as The Stoxx Europe 600 fell 1.03%, German

PREMIUM
MT Newswires 4 days ago

DZZ

UBS

^GDAXI
Aptar Digital to use AstraZeneca’s AI algorithms for CKD detection

The collaboration aims to integrate the algorithms into routine eye examinations, facilitating diagnosis.

Pharmaceutical Technology 4 days ago

AZN
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks 6 days ago

AZN
The Zacks Analyst Blog Highlights Visa, AstraZeneca, Shell, Ocean Power Technologies and Wheeler Real Estate Investment Trust

Visa, AstraZeneca, Shell, Ocean Power Technologies and Wheeler Real Estate Investment Trust are part of the Zacks top Analyst Blog.

Zacks 6 days ago

AZN

V

WHLR
AstraZeneca Stock Declines 6% in 3 Months: Time to Buy the Dip?

AZN's key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Fasenra are likely to drive sales in 2025.

Zacks 6 days ago

AZN
AstraZeneca’s record seventh year of plenary data at ASCO furthers ambition to redefine breast cancer care and transform outcomes in gastric cancer

WILMINGTON, Del., May 21, 2025--AstraZeneca advances its ambition to eliminate cancer as a cause of death with new data across its diverse, industry-leading portfolio and pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting, May 30 to June 3, 2025.

Business Wire 6 days ago

AZN

AZNCF
3 Promising Growth Stocks You Can Buy for Less Than $100

Investing in growth stocks is a great way to grow your portfolio in the long run. Three stocks that possess a lot of long-term potential and are cheap buys right now are Carnival (NYSE: CCL), AstraZeneca (NASDAQ: AZN), and Block (NYSE: XYZ). At less than $100 per share, here's why these can be good growth stocks to load up on today.

Motley Fool 6 days ago

CUK

AZN
Top Research Reports for Visa, AstraZeneca & Shell

Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), AstraZeneca PLC (AZN) and Shell plc (SHEL), as well as two micro-cap stocks Ocean Power Technologies, Inc. (OPTT) and Wheeler Real Estate Investment Trust, Inc. (WHLR).

Zacks 7 days ago

AZN

V

SHEL
AstraZeneca (LSE:AZN) Reports Positive AIRSUPRA Results Reducing Severe Asthma Risks

AstraZeneca (LSE:AZN) recently announced that its AIRSUPRA therapy significantly reduced severe asthma exacerbations, generating strong interest within the medical community. Over the last month, AstraZeneca's share price moved up by 2.45%, in line with broader market trends influenced by easing trade tensions and robust corporate earnings. The positive reception to AIRSUPRA at the American Thoracic Society conference, amid a generally positive sentiment in the pharmaceutical sector, likely...

Simply Wall St. 7 days ago

AZN

AZNCF
AstraZeneca says Airsupra reduced severe asthma risk by 47%

AstraZeneca (AZN) says “positive” full results from the BATURA Phase IIIb trial showed the company’s anti-inflammatory reliever rescue therapy, Airsupra, demonstrated statistically significant and clinically meaningful improvements in all primary and secondary endpoints compared to albuterol in patients with mild asthma. The trial measured as-needed Airsupra compared to as-needed albuterol. The BATURA trial demonstrated treatment with Airsupra significantly reduced the risk of a severe exacerbat

TipRanks 7 days ago

AZN

AZNCF
AstraZeneca PLC (AZN) Trial: Airsupra Cuts Severe Asthma Risk by 47%

AstraZeneca PLC (NASDAQ:AZN), a pharmaceutical and biotech firm based in Cambridge, UK, reported positive results from its Phase 3b Batura trial. The study found that Airsupra, its dual-action asthma rescue inhaler, led to meaningful improvements in patients with mild asthma compared to albuterol alone. AIRSUPRA is the only FDA-approved rescue inhaler designed to both relieve […]

Insider Monkey 7 days ago

AZN
Astrazeneca's Asthma Therapy Shows Improvement Across Primary and Secondary Endpoints in Late-Stage Trial

Astrazeneca (AZN) said Monday its phase 3b trial of Airsupra asthma rescue therapy showcased statist

PREMIUM
MT Newswires 8 days ago

AZN
Statistically significant and clinically meaningful BATURA Phase III trial results provide new evidence for AIRSUPRA as standard of care for as-needed rescue treatment in asthma

WILMINGTON, Del., May 19, 2025--Positive full results from the BATURA Phase IIIb trial showed AstraZeneca’s anti-inflammatory reliever rescue therapy, AIRSUPRA (albuterol/budesonide), demonstrated statistically significant and clinically meaningful improvements in all primary and secondary endpoints compared to albuterol in patients with mild asthma.1,2 These data were published in the New England Journal of Medicine and presented today at the American Thoracic Society (ATS) 2025 International C

Business Wire 8 days ago

AZN

AZNCF
Trump administration not backing down on Big Pharma pressure campaign

The pharmaceutical industry's patience is wearing thin with the Trump administration's pressure. But the administration doesn't care.

Yahoo Finance 10 days ago

LLY

RHHBF

RHHBY
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks 12 days ago

AZN
AstraZeneca’s growth prospects are as attractive as ever. Keep buying

AstraZeneca’s share price has risen by 39pc since our ‘buy’ recommendation in August 2019. In doing so, the FTSE 100’s largest company has beaten the wider index by 23 percentage points. Yet the near-term prospects for the global pharmaceutical firm have not always suggested that capital gains or index outperformance lie ahead.

The Telegraph 13 days ago

AZN

^FTSE
Is AstraZeneca (AZN) the Best Pharma Stock to Invest in Amid the Domestic Manufacturing Boom?

We recently published a list of Domestic Manufacturing Boom: 12 Best Pharma Stocks to Invest in Now. In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against other best pharma stocks to invest in now amid the domestic manufacturing boom. Trump Incentivizes Pharmaceuticals to Build Domestic Manufacturing Capacity […]

Insider Monkey 14 days ago

AZN

Performance Overview

Return	AZNN.MX	FTSE 100 (^FTSE)
YTD	+0.72%	+7.40%
1-Year	+3.29%	+5.54%
3-Year	+2.09%	+15.72%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

AstraZeneca PLC (AZNN.MX)

AstraZeneca (LSE:AZN) Gains EU Recommendation For Imfinzi in Bladder Cancer Treatment

AZN Gets CHMP Nod for Imfinzi in Muscle-Invasive Bladder Cancer

Roche Gets CHMP Nod for Itovebi Combo in the EU for Breast Cancer

European Equities Close Sharply Lower in Friday Trading; German Q1 GDP Expands 0.4% Sequentially

Aptar Digital to use AstraZeneca’s AI algorithms for CKD detection

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

The Zacks Analyst Blog Highlights Visa, AstraZeneca, Shell, Ocean Power Technologies and Wheeler Real Estate Investment Trust

AstraZeneca Stock Declines 6% in 3 Months: Time to Buy the Dip?

AstraZeneca’s record seventh year of plenary data at ASCO furthers ambition to redefine breast cancer care and transform outcomes in gastric cancer

3 Promising Growth Stocks You Can Buy for Less Than $100

Top Research Reports for Visa, AstraZeneca & Shell

AstraZeneca (LSE:AZN) Reports Positive AIRSUPRA Results Reducing Severe Asthma Risks

AstraZeneca says Airsupra reduced severe asthma risk by 47%

AstraZeneca PLC (AZN) Trial: Airsupra Cuts Severe Asthma Risk by 47%

Astrazeneca's Asthma Therapy Shows Improvement Across Primary and Secondary Endpoints in Late-Stage Trial

Statistically significant and clinically meaningful BATURA Phase III trial results provide new evidence for AIRSUPRA as standard of care for as-needed rescue treatment in asthma

Trump administration not backing down on Big Pharma pressure campaign

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

AstraZeneca’s growth prospects are as attractive as ever. Keep buying

Is AstraZeneca (AZN) the Best Pharma Stock to Invest in Amid the Domestic Manufacturing Boom?

Performance Overview